Escudier et al. (1818. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-34. Erratum in: N Engl J Med. 2007; 357: 203.) |
2007 |
903 |
NC |
Y |
Y |
2nd |
O |
Escudier et al. (99. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-11.) |
2007 |
649 |
A |
Y |
Y |
1st |
O |
Escudier et al. (1111. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, et al.: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysisof overall survival. J Clin Oncol. 2010; 28: 2144-50.) |
2010 |
649 |
A |
Y |
Y |
1st |
C |
Motzer et al. (1919. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-56.) |
2008 |
410 |
A |
Y |
Y |
2nd |
O |
Hudes et al. (1212. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-81.) |
2007 |
626 |
A |
Y |
NC |
1st |
O |
Yang et al. (1717. Yang S, de Souza P, Alemao E, Purvis J: Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer. 2010; 102: 1456-60.) |
2010 |
626 |
A |
Y |
Y |
1st |
C |
Escudier et al. (1010. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al.: Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 1280-9. Erratum in: J Clin Oncol. 2009; 27: 2305.) |
2009 |
189 |
A |
Y |
NC |
1st |
O |
Rini et al. (1515. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al.: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26: 5422-8.) |
2008 |
732 |
A |
Y |
N |
1st |
O |
Rini et al. (1616. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al.: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cellcarcinoma: final results of CALGB 90206. J Clin Oncol. 2010; 28: 2137-43.) |
2010 |
732 |
A |
Y |
N |
1st |
C |
Motzer et al. (1313. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-24.) |
2007 |
750 |
A |
Y |
N |
1st |
O |
Motzer et al. (1414. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cellcarcinoma. J Clin Oncol. 2009; 27: 3584-90.) |
2009 |
750 |
A |
Y |
N |
1st |
C |
Cella et al. (88. Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, et al.: Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol. 2008; 26: 3763-9.) |
2008 |
750 |
A |
Y |
N |
1st |
C |